Leadership Team

Trethera is led by a management team with a wealth of biopharma industry experience, spanning drug discovery, product development, CMC operations, and regulatory strategy. An accomplished Board of Directors and Scientific Founders supports Trethera.

Management Team

Kenneth Schultz, MD

Chairman, CEO, & President
Previous leadership roles at Halozyme, Medtronic, and McKinsey & Company

Evelina Rubinchik, PHD

Product Development
Previous leadership roles at Migenix and Micrologix

Joyce James, PHD

Clinical Pharmacology
Previous leadership roles at Lyric, Cytokinetics, and Merck

Chris Santos

CMC Regulatory
Previous leadership roles at Illumina, Kalypsys, and Victory

Cary Talbot

Chief Operating Officer
Previous leadership roles at Medtronic and Lockheed Martin

Meredith Brown-Tuttle

Clinical Regulatory
Previous leadership roles at Lyric Pharmaceuticals and NeurogesX

Board of Directors

Kenneth Schultz, MD

Chairman, CEO, & President
Former VP of Innovation, Strategy and Business Development, Halozyme Therapeutics; Previous leadership roles with Medtronic Diabetes and McKinsey & Company

Jean deKernion, MD

Director Emeritus
Professor and Former Chair, Department of Urology, David Geffen School of Medicine, UCLA; Former member of National Cancer Advisory Board; Co-founder of Agensys, Inc.

Timothy Donahue, MD

Board Member
Chief of Surgical Oncology and Professor of Surgery, UCLA School of Medicine

Louis Gonda

Board Member
CEO, Lexington Ventures; Former Board Director at the Mayo Clinic

Carl McKinzie, JD

Secretary
Former Partner, Bingham McCutchen; Former Partner, Riordan & McKinzie; Board Member, Sofie Biosciences

R. Boyd Quinnell, CPA

Board Member
Former CFO and General Manager, Biotronik (US); Controller and Senior Director of Finance, Medtronic

Laurent Dubois

Board Member
Former Partner, McKinsey & Company; Former CEO of GE Healthcare Partners

Trethera Advisors

Owen Witte, MD

UCLA; Trethera cofounder; discovered the BTK gene; Formerly Kite Pharma board director

Michael Shepard, PHD

Formerly Genentech; Distinguished Scientist and Lasker Laureate; Invented Herceptin

Johannes Czernin, MD

UCLA; Trethera cofounder; Ahmanson Translational Theranostics Division Chief

Rick Morrisey, PHD

Formerly Celgene Preclinical Development Head; President, American Board of Toxicology

Mike Jung, PhD

UCLA; Trethera cofounder; Discovered approved prostate cancer drugs Erleada and Xtandi

Larry Steinman, MD

Stanford; Discovered Tysabri; Won Dystel and Charcot Prizes for MS research

Frank Baxter

Formerly Jefferies bank Chairman and CEO; NASDAQ stock exchange director; US ambassador

Caius Radu, MD

UCLA; Trethera cofounder; Global authority regarding nucleotide metabolism pathways

Peter Clark, PHD

UCLA; Noted nucleotide metabolism preclinical researcher within autoimmune diseases

Michael Levy, MD, PHD

Harvard; Distinguished expert in rare neurologic diseases and neuroimmunology

David Nathanson, PHD

UCLA; Trethera cofounder; Neuroscience and Comprehensive Cancer Programs